Literature DB >> 31833150

Cannabis use, depression and self-harm: phenotypic and genetic relationships.

Karen Hodgson1,2, Jonathan R I Coleman1,2, Saskia P Hagenaars1,2, Kirstin L Purves1, Kylie Glanville1, Shing Wan Choi1, Paul O'Reilly1,3, Gerome Breen1,2, Cathryn M Lewis1,2.   

Abstract

BACKGROUND AND AIMS: The use of cannabis has previously been linked to both depression and self-harm; however, the role of genetics in this relationship is unclear. This study aimed to estimate the phenotypic and genetic associations between cannabis use and depression and self-harm.
DESIGN: Cross-sectional data collected through UK Biobank were used to test the phenotypic association between cannabis use, depression and self-harm. UK Biobank genetic data were then combined with consortia genome-wide association study summary statistics to further test the genetic relationships between these traits using LD score regression, polygenic risk scoring and Mendelian randomization methods.
SETTING: United Kingdom, with additional international consortia data. PARTICIPANTS: A total of 126 291 British adults aged between 40 and 70 years, recruited into UK Biobank. MEASUREMENTS: Phenotypic outcomes were life-time history of cannabis use (including initial and continued cannabis use), depression (including single-episode and recurrent depression) and self-harm. Genome-wide genetic data were used and assessment centre, batch and the first six principal components were included as key covariates when handling genetic data.
FINDINGS: In UK Biobank, cannabis use is associated with an increased likelihood of depression [odds ratio (OR) = 1.64, 95% confidence interval (CI) = 1.59-1.70] and self-harm (OR = 2.85, 95% CI = 2.69-3.01). The strength of this phenotypic association is stronger when more severe trait definitions of cannabis use and depression are considered. Using consortia genome-wide summary statistics, significant genetic correlations are seen between cannabis use and depression [rg = 0.289, standard error (SE) = 0.036]. Polygenic risk scores for cannabis use and depression explain a small but significant proportion of variance in cannabis use, depression and self-harm within a UK Biobank target sample. However, two-sample Mendelian randomization analyses were not significant.
CONCLUSIONS: Cannabis use appeared to be both phenotypically and genetically associated with depression and self-harm. Limitations in statistical power mean that conclusions could not be made on the direction of causality between these traits.
© 2019 Society for the Study of Addiction.

Entities:  

Keywords:  Cannabis use; Mendelian randomization; UK biobank; depression; genetic correlation; genetics; heritability; polygenic risk; self-harm

Year:  2019        PMID: 31833150     DOI: 10.1111/add.14845

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  10 in total

1.  Associations between adolescent cannabis use and young-adult functioning in three longitudinal twin studies.

Authors:  Jonathan D Schaefer; Nayla R Hamdi; Stephen M Malone; Scott Vrieze; Sylia Wilson; Matt McGue; William G Iacono
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

2.  Genetic correlation, pleiotropy, and causal associations between substance use and psychiatric disorder.

Authors:  Seon-Kyeong Jang; Gretchen Saunders; MengZhen Liu; Yu Jiang; Dajiang J Liu; Scott Vrieze
Journal:  Psychol Med       Date:  2020-08-07       Impact factor: 7.723

3.  Comorbidity and Coaggregation of Major Depressive Disorder and Bipolar Disorder and Cannabis Use Disorder in a Controlled Family Study.

Authors:  Courtney R Quick; Kevin P Conway; Joel Swendsen; Emma K Stapp; Lihong Cui; Kathleen R Merikangas
Journal:  JAMA Psychiatry       Date:  2022-07-01       Impact factor: 25.911

Review 4.  Associations between cannabis use, cannabis use disorder, and mood disorders: longitudinal, genetic, and neurocognitive evidence.

Authors:  Lauren Kuhns; Emese Kroon; Karis Colyer-Patel; Janna Cousijn
Journal:  Psychopharmacology (Berl)       Date:  2021-11-06       Impact factor: 4.415

5.  Studying individual risk factors for self-harm in the UK Biobank: A polygenic scoring and Mendelian randomisation study.

Authors:  Kai Xiang Lim; Frühling Rijsdijk; Saskia P Hagenaars; Adam Socrates; Shing Wan Choi; Jonathan R I Coleman; Kylie P Glanville; Cathryn M Lewis; Jean-Baptiste Pingault
Journal:  PLoS Med       Date:  2020-06-01       Impact factor: 11.069

Review 6.  Understanding the genetics and neurobiological pathways behind addiction (Review).

Authors:  Alexandra Popescu; Maria Marian; Ana Miruna Drăgoi; Radu-Virgil Costea
Journal:  Exp Ther Med       Date:  2021-03-23       Impact factor: 2.447

7.  Childhood Trauma and Non-suicidal Self-Injury Among Chinese Adolescents: The Mediating Role of Psychological Sub-health.

Authors:  Cui Huang; Qiuyu Yuan; Menglin Ge; Xuanlian Sheng; Meng Yang; Shengya Shi; Panpan Cao; Mengting Ye; Ran Peng; Ruochen Zhou; Kai Zhang; Xiaoqin Zhou
Journal:  Front Psychiatry       Date:  2022-02-10       Impact factor: 4.157

8.  Neurogenetic and Epigenetic Aspects of Cannabinoids.

Authors:  Catherine A Dennen; Kenneth Blum; Abdalla Bowirrat; Jag Khalsa; Panayotis K Thanos; David Baron; Rajendra D Badgaiyan; Ashim Gupta; Eric R Braverman; Mark S Gold
Journal:  Epigenomes       Date:  2022-08-26

Review 9.  A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration.

Authors:  Kenneth Blum; Shan Kazmi; Edward J Modestino; Bill William Downs; Debasis Bagchi; David Baron; Thomas McLaughlin; Richard Green; Rehan Jalali; Panayotis K Thanos; Igor Elman; Rajendra D Badgaiyan; Abdalla Bowirrat; Mark S Gold
Journal:  J Pers Med       Date:  2021-03-16

10.  Using Mendelian randomization analysis to better understand the relationship between mental health and substance use: a systematic review.

Authors:  Jorien L Treur; Marcus R Munafò; Emma Logtenberg; Reinout W Wiers; Karin J H Verweij
Journal:  Psychol Med       Date:  2021-05-25       Impact factor: 7.723

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.